Posted on 26 SEP 2011: Adelaide, South Australia (September 26, 2011) – vivoPharm Pty Ltd is pleased to announce that Ian Nisbet, PhD, MAICD has joined its Board of Directors and has been appointed as the new Chairman of the Board.
Dr Nisbet has over 30 years of drug development, business development and general management experience in the local and international biotechnology sector. He is a founder and partner in the biotechnology consulting company Afandin Pty Ltd; a former CEO/Managing Director of Xenome Ltd and Meditech Research Ltd; and has held senior management positions at Millennium Pharmaceuticals Inc, ChemGenex Pharmaceuticals Ltd and CSL Ltd. Ian is Chairman of Verva Pharmaceuticals Ltd, a non-Executive Director of Velacor Pty Ltd and Deputy Director (Commercialisation) at the Australian Institute for Bioengineering and Nanotechnology (AIBN).
“vivoPharm has established a successful service business in Australia and is poised to establish its presence in the US. It is an honour to join the Board at this time and I look forward to using my knowledge and networks in the oncology sector to help build vivoPharm into the premier global oncology-focused preclinical contract research organisation” said the newly-appointed Chairman.
Dr Ralf Brandt, vivoPharm’s founder, CEO and Managing Director said “It is a privilege for our company to leverage the networks and experience of someone of Ian’s caliber to help us navigate the very exiting times ahead”.
Dr Brandt also thanked the outgoing Chairman, Mr Brenton Wright (who continues as a non-Executive Director) for his guidance to the company during its formative years.
vivoPharm has recently opened a new facility in Hershey, Pennsylvania which adds to its presence in Adelaide, Australia and Munich, Germany. It also recently announced a strategic alliance with MPI Research, the largest single-site pre-clinical CRO worldwide. As a consequence of these initiatives, the company expects rapid growth in the demand of its pre-clinical services in the North American region.
For more information, please contact Dr. Fernando Felquer, vice president of global commercial development, firstname.lastname@example.org.